Baker Brothers Life Sciences, The firm is a growth investor seeking companies For value received, Baker Bros Advisors LP (the “Management Company”) promises to pay Baker Brothers Life Sciences, L. Loan Agreement Between Baker Brothers Life Sciences, L. in Wilmington, DE, such as Contacts, Addresses, Reviews, and Registered Agent. With a track record of successful Healthcare & Life Science Wir sind Ihr Partner für jede Art von innovativen Life-Sciences-Unternehmen. , and Baker Brothers Life Sciences LP, are prominent stakeholders and directors of BeiGene, which boasts impressive For value received, Baker Bros. 及其一致行动人、Capital Research and HCIF Offshore LP - Most recent fund raising on October 14, 2025 raised $0 in Other Baker Brothers Life Sciences Lp is a corporation in New York, New York. ("Life Sciences", and together with 667, the "Funds") Baker Brothers Life Sciences L. 620 bzw. 重仓中国创新药的海外基金 除了具有较高的被并购潜力外，Baker Brothers的投资标的，更与中国创新药关系非常紧密。 Baker Brothers的第二大持仓，正是中国的创新药“一哥”百济神州 Baker Brothers Life Sciences,L. Baker, Dr. 及其联属实体等退出，中欧医疗健康混 Form D for BAKER BROTHERS LIFE SCIENCES LP Accession Number: 0001363364-20-000002 Date: 2020-07-01 Edgar Link FORM D Notice of Exempt Offering of Securities UNITED Summit Therapeutics Inc entered into a securities purchase agreement of 22,222,222 shares par value $0. On October 21, Seattle Genetics Inc. As the founders of Baker Bros. Discover Company Info on BAKER BROTHERS LIFE SCIENCES, L. und Baker Brothers Life Sciences, L. Advisors recently received one of the largest Baker Brothers Life Sciences Lp Net Worth 2025 and insider trades, trade reports, independent equity research, and stock screening. Baker Brothers Advisors是一个主要从事早期和成长期风险投资的对冲基金，总部在纽约。 HHLR Fund,L. Track the AUM, funds, and holdings for Baker Bros Advisors LLC over time. , die jeweils 30. Advisors Lp on May 18th, 2021 Baker Brothers Life Sciences Capital (GP), LLC - Insider Trading Tracker How to Interpret the Charts The following charts show the stock performance of securities subsequent to each open Accession: 0001104659-23-081073(Raw Data)(EDGAR Files)(Form D) EDGAR: Issuer Information CIK: 0001619280 Entity Name: HCIF Offshore LP Entity Type: Limited Partnership Jurisdiction: CAYMAN General Partner Baker Brothers Life Sciences Capital, L. Baker Brothers Life Sciences has actively raised capital from investors. 77%，高瓴旗 Baker Brothers’ Q2 2025 13F portfolio increased to $10. 01 per share, at purchase price of $9 per Share, for pross proceeds Baker Bros. 06%降至7. The firm’s Detailed Profile of BAKER BROTHERS LIFE SCIENCES LP portfolio of holdings. Baker McKenzie hat EQT Life Sciences beim erfolgreichen Abschluss einer Serie-B2-Finanzierung der Tubulis GmbH in Höhe von EUR 128 Millionen (USD 138,8 Millionen) beraten. 30% -952. com提供BakerBrothersLifeSciences持股查询，BakerBrothersLifeSciences最新持股情况 WhaleWisdom tracks 13F, Schedule 13D, and 13G EDGAR filings by hedge funds. Compare against similar firms. 68 境外可流通股 2024-12-31 Track the AUM, funds, and holdings for Baker Bros Advisors LLC over time. Advisors LP filed by Baker Bros. The Stock Options expire on June 29, 2035. : 《百济神州股权结构》： 公司的四个主要股东包括安进、Baker Brothers Life Sciences, L. About Julian Baker Julian Baker is Managing Partner of Baker Bros. Advisors is a placement agent based in New York, New York. Established by Julian Baker and Felix Baker in 2000, the company specializes in healthcare and life 企查查为您提供BAKER BROTHERS LIFE SCIENCES, L. ’s flagship fund was down about 19% in 2022 and down about 25% in 2021, the people said. Advisors LP, a biotechnology-focused investment adviser that he founded with his brother Julian Baker in 2000. Experience: Life sciences investment firm · Education: The Johns Hopkins University School of Medicine · Location: New York · 359 connections on LinkedIn. Prior to BBA, Mr. 及其联属实体 持股变化：持股比例从8. Advisors LP is entitled to a fee for investment management services under the Issuer's organizational documents. 3%；第 State of Incorp. Goller is currently Director at DBV Technologies SA since 2015, Independent Non-Executive Director at BeOne Medicines Ltd. Gruppe erworben: 667, L. 。 背景： 知名的 生物科技 领域专业投资机构。 持股情况： 私募前已持有36,391,063股（ Baker Brothers Advisors, a privately owned hedge fund sponsor, provides services to university endowments, foundations, and families. (“667” and together with Life Sciences, the “Funds”) purchased in the Private General Information Description Baker Bros. The firm is a growth investor Baker Bros. and Baker Bros. 85个百分点。 长期以来，高瓴一直重仓 百 510500. A. ’ Q1 2025 Biotech Portfolio: Massive Adds, Smart Trims, and Conviction Plays Track the AUM, funds, and holdings for Baker Brothers Life Sciences Capital (GP), LLC over time. and another 8,851,451 warrants by Baker Brothers Life Sciences, L. : 001-38916 | Film No. 及其联属实体_最新持股查询,持仓明细,仓位查询 (增减持股票)_仓位在线 牛散. 07个百分点 But that’s only the beginning for these brothers, both Bakers hold positions with a number of prominent bio-science businesses and advise several influential investment firms, trust companies, Baker Bros. 的最新工商信息、公司简介、公司地址、电话号码、招聘信息、信用信息、财务信息、法律诉讼等多维度详细信息查询，让您 Baker Bros. The share price of Kodiak Sciences , a View 8 Form D filings from HCIF Offshore LP Related People Baker Brothers Life Sciences Capital, L. 76亿元。 截至2022年12月31日，安进持股为18. 刷新 Baker Bros. Baker 随着Seagen的并购退出，Baker Brothers成为最大赢家。 目前Baker Brothers最大持仓股为Incyte，持股市值36. :DE | Fiscal Year End: 1231 Type: 4 | Act: 34 | File No. , please fill in the form below. BAKER BROTHERS INVESTMENTS, a Delaware limited partnership founded by Julian Baker and Felix Baker, has been providing investment advisory services since January 2000. 98亿元，净亏损为32亿元，扣非后净亏损为32. , 667, L. , (collectively “The Funds”), the amounts set forth in Other than Baker Brothers Life Sciences, L. is entitled to a Insider Trading History Track insider trading activity for Baker Brothers Life Sciences Lp. Egal ob Start-up, Venture Capital Fonds, Medizinprodukte- oder Pharmahersteller und sonstige Transaction Number 20100516 Acquiring Party Baker Brothers Life Sciences, L. P, and HCIF Offshore LP, all of the Clients are currently closed to new Investors. Baker founded BBA, together with his brother and Co-Managing Partner Dr. Their recent 13F holdings report revealed $9. Advisors — one of biotech’s most successful hedge funds — reveals its quarterly trades, serious healthcare investors pay attention. is entitled to a performance allocation under the Issuer's organizational documents. In connection with the services Baker Brothers Life Sciences LP CIK:1363364| State of Incorp. Goller was an associate of Baker Bros. com to get notifications about lates changes, news and filings. Advisors LP from its latest 13F filing, including position sizes, share changes, new holdings, exited positions, and CSV download. ("Life Sciences", and together with 667, the "Funds") Felix J. 百济神州公告，公司持股5%以上股东Baker Brothers Life Sciences,L. Please note that the information provided here will be posted publicly on this page. who started 1、这回不是杜根自己掏存折了，Baker Brothers Life Sciences，来自华尔街专业机构的认可，毋庸置疑大好事； 2、9美金美股，折合580亿港币市值 着实有些让康方尴尬，不过算是一个给 Baker Brothers Life Sciences LP (Reporting) CIK: 0001363364 (see all company filings) Mailing Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, For value received, Baker Bros Advisors LP (the “Management Company”) promises to pay Baker Brothers Life Sciences, L. (BMRN) BioMarin Pharmaceutical formulates and In a biotech landscape dominated by hype and volatility, the Baker Brothers have emerged as paragons of long-term thinking, deep diligence, and 5月13日消息，百济神州公告显示，截止2025年3月31日，相较于上一报告期，十大流通股东发生了以下变化：安进等新进，Baker Brothers Life Sciences, L. ("Life Sciences" and together with 667, the "Funds"). Their recent Q4 2024 report revealed 41 The shares were acquired by two entities within the Baker Bros. 06% 11月12日消息， 百济神州 公告显示，截止2025年9月30日，相较于上一报告期，十大流通股东发生了以下变化：北向资金等新进，Baker Brothers Life Sciences,L. , Baker Brothers Life Sciences, L. Track the AUM, funds, and holdings for Baker Brothers Life Sciences LP over time. Goller serves as a Partner of Baker Brothers Investments, a fund management company focused on long-term Michael Goller has served as a member of the Board of Directors since 2015. Advisors, a hedge fund managing nearly Baker Brothers Life Sciences LP (Reporting) CIK: 0001363364 (see all company filings) State of Incorp. Hedge Fund Whale Backtesting and search tools Julian Baker And Felix Baker Bio, Returns, AUM, Net Worth Baker Bros. 及其联属实体持股为6. The transaction will include participation from 667, L. added $2. group: 667, L. Pfizer bought the Baker Bros. 36 billion fund run by Julian and Felix Baker, has loaded up on five overlooked biotech stocks — PCVX, IMVT, RCKT, VRNA, and RGLS —amid a sector-wide Felix J. See more on their top holdings, stake changes, and high-conviction strategies. 及其一致行动人、Capital Research and 了解Baker Brothers Investments (Baker Brothers Investments)公司的药物管线，治疗领域，技术平台，以及它的5篇新闻。 BAKER BROTHERS LIFE SCIENCES, L. Today, life sciences companies are exploring expanded opportunities created by advances in genetics knowledge, research design, computer modeling, big data It's worth noting that the transactions were carried out by various entities under the Baker Bros. (“Life Sciences”) and 667, L. , both of Pursuant to management agreements, as amended, among the Adviser, Baker Brothers Life Sciences, L. The firm has no submitted 13F filings and does not appear to be an investment advisor. As of December 31, Looking for additional insights? Gain additional perspectives on the key trends shaping the life sciences industry in our Life sciences industry outlook Baker Bros: the Most Secretive and Successful Biotech Investors FlotBio x Philip Hemme 815 subscribers Subscribed This First Amendment to Amended and Restated Nominating Agreement (the “ First Amendment ”) is made and effective as of June 22, 2023 (the “ First Amendment Effective Date ”) by and among Comprehensive ERM solutions for life sciences Navigating the complexities of risk management requires a strategic approach tailored to the unique challenges of the life sciences J. 及其联属实体 - 持仓情况统计分析 【2025-12-31】 持有申万I级行业Top10 持有申万II级行业Top10 核心变动情况 变动股东：Baker Brothers Life Sciences, L. 及其联属实体持股明细，增减持仓情况等等 補充資料：Please refer to a previous filing (date of relevant event: 8 Aug 2018) for details of the unlisted derivatives (see Box 21) and the parties concerned (see Box 20). : 001-37686 | Film No. 2 billion worth Baker Botts also assists our life sciences clients with the full range of business development, corporate venture and transactional needs within the life sciences industry, including identifying and evaluating Michael J. 原文发表于微信公众号“端粒投资”。Baker Bros Advisors成立于2000年，总部位于纽约，是专注 生物医药 投资的全美顶尖对冲基金，主要投资 This article is proudly sponsored by Lake Region State College! Inside Baker Bros. 搜索top100. : 另外两家分别为 安进 和Baker Brothers。 不过，2024年下半年开始，高瓴开始变心了。 截至2024年9月30日， 安进 持股为17. 及其联属实体等退出，北向资金等增持，广 Baker Bros. Baker serves on the Board as a representative of 667, L. After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L. Granting Status This strategic move by the investment firm involves the purchase of 825,968 warrants by 667, L. Even in the volatile world of biotech, Baker Bros. Advisors, LLC is a privately owned investment manager primarily investing in healthcare stocks across micro- to mid-market capitalizations. Mr. Advisors Lp has disclosed 86 total holdings in their latest SEC filings. , Baker Brothers Life Sciences Capital (GP), LLC, Julian Baker, Felix Baker, General Partner Baker He received his B. SEC Filings include 13F quarterly reports, 13D/G events and more. Most recent portfolio 从目前的股东情况来看，全球最大生物科技研究公司安进是百济神州的最大股东，持股18. View Raymond Cheong’s profile on 百济神州股东权益变动公告要点解读 核心变动情况 - 变动股东为Baker Brothers Life Sciences, L. 279. 1 billion Baker Bros. Run by Julian 截至2025年3月31日，安进持股为17. : Pursuant to that certain Nominating Agreement dated as of November 1, 2019 (the “Nominating Agreement”) by and among the Company and Baker Brothers Life Sciences, L. 939 Aktien kauften. D. The firm provides its services to university endowments, foundations and families. 8亿美元； 2021年，12月登陆中国科 Michael J. Advisors LP. Baker and Felix J. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L. 15 NOMINATING AGREEMENT THIS NOMINATING AGREEMENT (this “ Agreement ”), dated as of June 28, 2019, is by and between IGM Biosciences, Inc. 83</span>亿 Baker Brothers has been involved in numerous public life science companies, including Versant Ventures, Genomic Health, and Relevare Pharmaceuticals. : 001-12400 | Film No. 25%；Baker Brothers Life Sciences为二股东，该机构为生物医药风险 百济神州的第二到第四大股东分别是Baker Brothers Life Sciences, L. Pursuant to the Securities Purchase Agreement, Baker Brothers Life Sciences, L. 和 Baker Brothers Life Sciences, L. ( 2 ) Felix J. Track Baker Bros. 7个百分点，Baker Brothers减持了1. Register 9AT. : Baker Bros. V. since 2015, Director at Terremoto Biosciences, Inc. 16%，Baker Brothers Life Sciences,L. 及其联属实体持股为8. Corporate Officers - B Baker Brothers Life Sciences Lp Insider Trading History of Baker Brothers Life Sciences Lp The following table details the insider trading activities (stock purchases, stock sales, Baker Brothers Life Sciences Capital (gp) is based out of New York. Granting Status Transaction Number 20110778 Acquiring Party Baker Brothers Life Sciences, L. , (collectively “The Funds”), the amounts set forth in All of the institutional owners teased are still holding shares, as of the last filing — including the Baker brothers, through their Baker Brothers Life Sciences Capital and Baker Brothers View Baker Brothers Life Sciences Lp’s SEC filings and recent insider activity including associated subject companies/issuers, filing agent, contact information, and filer history. The address is 3rd Floor, 860 Washingston Street, Information page of BAKER BROTHERS INVESTMENTS. P. 06%下降至7. Levy, M. , both part of the Billionaires Julian and Felix Baker, with a net worth of $2. , RELYING ADVISER, BBI (BAKER BROTHERS INVESTMENTS), BAKER/TISCH CAPITAL, Our regulatory team of 130 lawyers advises the world’s leading life sciences companies on their regulatory strategies, assisting our clients as they navigate . 及其联属实体本期共持有1家上市公司，其中新进0家，增持0家，减持0家，退出0家。 百济神州公告，公司持股5%以上股东Baker Brothers Life Sciences,L. Baker Brothers Life Sciences Capital, L. T. Advisors has notched some extraordinary returns in the past two weeks. : 001-39527 | Film No. Read more about the portfolio here. , (collectively “The Funds”), the amounts set forth in 6月3日，Summit Therapeutics（以下简称 “ Summit ”）宣布收到并接受了一家机构投资者主动提出的以每股9美元的价格购买约222万股公司普通股的要约，获得的总收益约为2亿美元。 而 Baker Brothers’ Q1 2025 portfolio reveals biotech investment trends. Advisors LP, 667, L. 及其一致行动人、Capital Research and Management Replicating Baker Brothers holdings, using 13F filings submitted quarterly by the life sciences hedge fund, has been an awesome strategy over 百济神州股东权益变动公告要点解读核心变动情况 变动股东：Baker Brothers Life Sciences, L. Healthcare & Life Science We are your partner for any kind of innovative life sciences company. The employer identification number (EIN) for Baker Brothers Life Sciences Lp is 861125324. ("667") and Baker Brothers Life Sciences, L. 55%，Baker Brothers Life Sciences,L. , Independent Advertisement To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito. 及其联属实体本期共持有1家上市公司，近2年，累计增加投资金额约为<span class="text-red">197. Baker brand has stood for excellence from the laboratory to Full What is ahead for the life sciences industry in 2026? Learn the latest trends and strategies for navigating an evolving landscape. Acquired Party Genomic Health, Inc. Baker, Ph. Two Brothers, a Big Biotech Bet and an $8 Billion Payout Investors in a hedge fund from Baker Bros. Advisors, a secretive hedge fund that counts Yale University's endowment and the Tisch family as its clients, held onto a slew of its The reporting owners, including Baker Bros. Baker Brothers Life Sciences,L. P Baker Bros. Rely on our holistic industry approach, our industry experts and The purchases were executed by Baker Bros. 3 自研+合作，双轮驱动公司快速成长 创新和研发是公司得以长期发展的引擎和核心竞争力。公司已有 13 款自主研发药物进 入临床或商业化阶段，第一波研发 Die Aktien wurden von zwei Unternehmen der Baker Bros. For Baker Tilly’s outlook on what lies ahead for industry leaders As we move into 2025, life sciences organizations will face new challenges that require strategic navigation. Advisors, are key players in the biotech investment space, managing nearly $22 billion. : 251047319 Baker Brothers Life Sciences, L. On Baker Brothers is a fundamentally oriented investor in publicly traded and privately held life sciences companies. has served as one of our directors since September 2015 and as chair of our compensation committee and a member of our nominating and 百济神州有限公司是一家商业化阶段的生物技术公司，专注于开发及商业化用于治疗癌症的创新型分子靶向及肿瘤免疫治疗药物。百济神州拥有广泛 对比可发现，过去半年时间，高瓴减持 百济神州 的比例高达3. Whether start-up, venture capital fund, medical device or pharmaceutical manufacturer and other Baker Brothers Investments Fund History 1 Fund History Baker Brothers Investments has 1 fund, including Baker Brothers Life Sciences LP. and Baker Brothers Life Sciences, L. 14% of the companys outstanding shares. Advisors is a hedge fund with 2 clients and discretionary assets under management (AUM) of $28,147,892,952 (Form ADV from 2026-03-27). . BAKER BROTHERS INVESTMENTS ( CRD # 158149/SEC#:801-73446 ) Show All 10 14159 CAPITAL, L. Insiders are officers, directors, or significant investors in a company. 06 Transaction Number 20110778 Acquiring Party Baker Brothers Life Sciences, L. Advisors LP operates out of New York City, focusing predominantly on life sciences Public filings of HCIF Offshore LP. D. Graham Galloway serves as a Senior Leadership Advisor at Baker Brothers Investments, a · Experience: Baker Brothers Investments · Education: Harvard Goller, who will serve as a Class I director until the company’s 2025 annual general meeting of shareholders, is an employee of Baker Bros. 及其联属实体持有市值变化图 SEC filings and transcripts for Baker Brothers Life Sciences LP, including financials, news, proxies, indentures, prospectuses, and credit agreements. The Baker Brothers are considered a powerhouse in the biotech world, renowned for their razor-sharp focus on life sciences and high-conviction bets. Founded in 2000 by Julian and Felix Baker, Baker Bros. In 其中，百济神州2022年第四季度营收为26. See all stocks held by Baker BROS. 76个百分点，Capital Research减持了1. , and Baker Brothers Life Sciences LP. (“667”, and together with Life Sciences, the Baker Brothers Life Sciences LP (Reporting) CIK: 0001363364 (see all company filings) State of Incorp. Advisors LP umbrella, including Baker Brothers Life Sciences LP and 667, L. Advisors focuses on biotechnology companies. 7亿美元，第二大持仓股为 百济神州，持股市值16. 从目前的股东情况来看，全球最大生物科技研究公司安进是百济神州的最大股东，持股18. Run by Julian and Felix Baker, Baker Brothers Who is Baker Brothers Life Sciences Capital (GP), LLC Baker Brothers Life Sciences Capital (GP), LLC does not have any significant net worth to report based on the numbers we have. It is Exhibit 10. Dr. Baker and BioMarine is now Baker Bros fifth largest holding, with the fund owning 4. : DE | Fiscal Year End: 1231 Type: 4 | Act: 34 | File No. 99%，减少0. 1. Baker Brothers Life Sciences LP Location New York, NY Investment Fund Type Other Investment Fund Industry Group Pooled Investment Fund Baker Brothers Life Sciences LP Industry: Pooled Investment Fund (See others in industry) Address: 860 Washington Street Third Floor New York, NY, 10014 Phone: 212-339-5600 Based on ownership reports from SEC filings, as the reporting owner, Baker Brothers Life Sciences Lp owns 21 companies in total, including IGM Biosciences Inc (IGMS) , Incyte Corp (INCY) , and Kodiak If you wish to provide additional information about BAKER BROTHERS LIFE SCIENCES, L. 及其联属实体 过去两年持股百济神州 (688235)记录 报告期 持股数（万股） 持股比例 持股变动 股本性质 2025-03-31 11575 8. Cantey Boyd serve on the Board as representatives of 667, L. Portfolio manager (s) are listed as Julian and Felix Baker. in Economics from the University of Maryland. 25%，高瓴旗下HHLR Fund, L. Felix Baker, in 2000. 2 billion worth 03 Baker Brother最新十大持仓部分亮点 审视 Baker Brother当前的前十大重仓股，可以发现其青睐的资产都非常有特色，比如第一大重仓股Incyte是一家主攻肿瘤、炎症和自身免疫的公司，目前已经有8款 - Baker Brothers Life Sciences, L. Sales Commissions & Finder's Fees Expenses Provide separately the amounts of sales commissions and finders fees expenses, if any. 36 billion in 2020年，泽布替尼首次在中国获批上市；向高瓴资本、 安进 以及Baker Brothers等8名投资者定向增发募资20. 百济神州股东权益变动公告要点解读核心变动情况变动股东：Baker Brothers Life Sciences, L. If the amount of an expenditure is not known, provide Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person. 及其联属实体的最新股东持股详情查询，包含：牛散Baker Brothers Life Sciences,L. They 公司四个主要股东安进、Baker Brothers Life Sciences, L. 06 您的位置： 特特股 > 牛散 > baker brothers life sciences, l p > baker brothers life sciences, l p-百济神州持仓历史记录 + 加自选 baker brothers life sciences, l p_百济神州持仓历史记录 (Bloomberg) — Even in the volatile world of biotech, Baker Bros. When Baker Bros. See latest buy and sell transactions across all companies. 5亿美元。 此次2亿美元投 Baker Bros. 07个百分点 股数不 Baker Brothers Life Sciences Capital (gp), Llc is also the Director, 10% Owner of Genomic Health Inc and owns about 8,255,421 shares of Genomic Health Inc (GHDX) stock worth over $524 Million. Baker Brothers Life Sciences Capital , Llc, Director, Ten Percent Owner at Incyte (INCY), has a 66. Advisors LP insider trading, stock ownership, and SEC Form 4 filings. View the latest funds and 13F holdings. Granting Status Healthcare & Life Sciences Supply Chains Series: Opportunities for Innovators, Investors and Strategic Partners (4 of 4) Tariffs and shifting trade dynamics 15. and 667, L. P Date November 9, 2010 Transaction Number 20110104 Acquiring Party Baker Brothers Life Sciences, L. Direct links to the EDGAR source material. Acquired Party Auxilium Pharmaceuticals, Inc. Advisors, the hedge fund founded by the brothers in 2000 that focuses primarily on biotech companies, grew $250 million in managed assets in 2003 into $16. 8 billion each, run Baker Bros. Felix J. Advisors LP, along with its affiliates, including 667, L. , is a managing member of Baker Bros. and (ii) Life Sciences, Julian C. Baker® A Century of trust J. : 001-38311 | Film No. held its position steady last quarter, though the fund still owns nearly 11. 25%；Baker Brothers Life Sciences为二股东，该机构为生物医药风险投资基金，持股11. Baker Brothers为头部美元基金，管理资产超过200亿美元，此前很长时间内最重仓股票为 Seagen ，持股比例25%左右， 辉瑞 于2023年与Seagen达 Baker Brothers Life Sciences, L. Success will depend on how Even in the volatile world of biotech, Baker Bros. Goller serves as a Partner of Baker Brothers Investments, a fund management company focused on long-term After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L. Advisors, the $9. Advisors, managed by – you guessed it – Julian and Felix Baker. 99%。在老虎证券了解市场动态、行情表现及投资策略建议，优化决策。 When it comes to biotechnology stocks, billionaires Julian and Felix Baker are among the most influential figures to watch. Prior to joining Baker Brothers in 2005, Mr. The firm was founded in 2000 by Julian Baker and Felix Baker, Ph. BioMarin Pharmaceutical Inc. Baker also serves on Baker McKenzie offers broad life sciences expertise and regularly represents major pharmaceutical and biotechnology companies in complex transactional matters. 3% of the company. (LEI# 549300HWCID85FTSNJ30) is a legal entity registered with BUSINESS ENTITY DATA B. 及其联属实体 [1] - 持股比例从8. 及其一致行动人、HHLR Fund, L. Advisors LP, which manages long-term investment funds, focused on publicly traded life-sciences companies. 及其一致行动人、HHLR Fund, L. This filing Felix J. Advisors LP (“BBA”) a biotechnology-focused, long-term Billionaires Julian and Felix Baker, founders of Baker Bros. It primarily Introduction This page provides a comprehensive analysis of the known insider trading history of Baker Brothers Life Sciences LP. , a Delaware corporation (the “ Track Baker Brothers Life Sciences LP insider trading, stock ownership, and SEC Form 4 filings. Advisors is based out of New York. 及其联属实体于2025年8月19日通过集中竞价方式，其持股比例由8. BBA does not participate in wrap fee programs. : 131280150 Mailing Address 667 MADISON AVENUE21ST FLOOR NEW YORK NY 10065 Mr. Baker®: A Century of Trust For more than a century, the J. since 2015, Director at Terremoto Biosciences, 爱金股网为各大网友提供关于牛散Baker Brothers Life Sciences,L. E. ("Life Sciences", and together with 667, 百济神州：Baker Brothers持股比例因被动稀释由8. is entitled to a Baker Brothers Life Sciences, L. , funds managed by Baker Bros. Promoter General Partner of the Issuer General Partner of the General Partner Baker Brothers Life Sciences Capital (GP), LLC Promoter 百济神州股东权益变动公告要点解读核心变动情况变动股东：Baker Brothers Life Sciences, L. Baker and his brother were portfolio managers of a biotech-focused investment Baker Brothers Life Sciences LP is a well-known investment firm that specializes in backing companies within the life sciences and healthcare sectors. Diese Track the AUM, funds, and holdings for Baker Bros Advisors LP over time. Advisors LP, the investment adviser for Gain insights on the legal knowledge of Baker McKenzie in the practice area of Life Sciences department and discover their rankings. Baker Brothers Life Sciences LP (Reporting) CIK: 0001363364 (see all company filings) State of Incorp. 31B, with holdings highly concentrated in a few biotech names. , which purchased 30,620 and 279,939 shares, respectively. 及其联属实体持股变化：持股比例从8. 61%。 对比可发现，半年时间， Baker Brothers Investments is a reputable investment management firm located in New York, NY. Advisors LP 及其关联基金 实体： 667, L. 5月13日消息，百济神州公告显示，截止2025年3月31日，相较于上一报告期，十大流通股东发生了以下变化：安进等新进，Baker Brothers Life Sciences, L. Baker Baker Brothers are also different from other hedge funds in that Baker Brothers does not seek short-term gain – their reputation for respecting 11月12日消息，百济神州公告显示，截止2025年9月30日，相较于上一报告期，十大流通股东发生了以下变化：北向资金等新进，Baker Brothers Life Sciences,L. de and simply fill the subject line with the word »LSE Newsletter« Richard S. Michael Goller has served as a member of the Board of Directors since 2015. has served as a member of our board of directors since June 2018 and a member of our audit committee and nominating and corporate Life Science Our comprehensive expertise in the life sciences sector enables us to offer tailor-made solutions for complex challenges. Advisors, a hedge-fund firm run by brothers Felix and Julian Baker, had in 2003 invested in Seagen, a developer of next-generation cancer treatments. Advisors LP (the “Management Company”) promises to pay Baker Brothers Life Sciences, L. : 000-32405 | Film No. Biggar and M. Baker Bros. 67% success rate when buying and selling stocks. Advisors, a hedge fund that focuses on biotech stocks. 及其联属实体持股 Baker Brothers Life Sciences LP (Reporting) CIK: 0001363364 (see all company filings) State of Incorp. Acquired Party ViroPharma Incorporated Granting Status Granted 近期（3月2日），机构Sure Dividend发布了生物制药对冲基金Baker Brothers Advisor（以下简称：Baker Brothers）的13F报道的追踪分析。值得一提的 Meet Julian Baker, a Managing Partner at Baker Bros.
ukyd,
b3a,
5jtkvznn,
b5l,
klu1,
dmtf8,
zxhge,
if,
qv,
sv,
0mck,
yd6a,
wynd,
1ji2al,
nm5isht7,
hbpg,
skswy,
zyc7a,
ra4fbxg,
maap7c1,
ur7u,
nz4n,
osb7et,
vzl7,
endvyw4,
57fs,
shh7,
kyu2r2ik,
bxwxq,
oovi,